DE2315801C3 - 2-Alkyl-3-acyl-pyrazolo [1,5-a] pyridine, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneipräparate - Google Patents

2-Alkyl-3-acyl-pyrazolo [1,5-a] pyridine, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneipräparate

Info

Publication number
DE2315801C3
DE2315801C3 DE2315801A DE2315801A DE2315801C3 DE 2315801 C3 DE2315801 C3 DE 2315801C3 DE 2315801 A DE2315801 A DE 2315801A DE 2315801 A DE2315801 A DE 2315801A DE 2315801 C3 DE2315801 C3 DE 2315801C3
Authority
DE
Germany
Prior art keywords
pyrazolo
pyridine
alkyl
pyridines
isopropyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE2315801A
Other languages
German (de)
English (en)
Other versions
DE2315801A1 (de
DE2315801B2 (de
Inventor
Junji Kitamoto Hatayama
Masayuki Ageo Hayashi
Etsuko Urawa Hetsugi
Tsutomu Tokio Irikura
Kikuo Koshirae
Yoshitaka Kudo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyorin Pharmaceutical Co Ltd
Original Assignee
Kyorin Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyorin Pharmaceutical Co Ltd filed Critical Kyorin Pharmaceutical Co Ltd
Publication of DE2315801A1 publication Critical patent/DE2315801A1/de
Publication of DE2315801B2 publication Critical patent/DE2315801B2/de
Application granted granted Critical
Publication of DE2315801C3 publication Critical patent/DE2315801C3/de
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE2315801A 1972-03-30 1973-03-29 2-Alkyl-3-acyl-pyrazolo [1,5-a] pyridine, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneipräparate Expired DE2315801C3 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP47032033A JPS5229318B2 (enExample) 1972-03-30 1972-03-30

Publications (3)

Publication Number Publication Date
DE2315801A1 DE2315801A1 (de) 1973-10-11
DE2315801B2 DE2315801B2 (de) 1978-06-22
DE2315801C3 true DE2315801C3 (de) 1979-02-22

Family

ID=12347544

Family Applications (1)

Application Number Title Priority Date Filing Date
DE2315801A Expired DE2315801C3 (de) 1972-03-30 1973-03-29 2-Alkyl-3-acyl-pyrazolo [1,5-a] pyridine, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneipräparate

Country Status (12)

Country Link
US (1) US3850941A (enExample)
JP (1) JPS5229318B2 (enExample)
AR (1) AR197709A1 (enExample)
BE (1) BE797554A (enExample)
BR (1) BR7302268D0 (enExample)
CA (1) CA989843A (enExample)
DE (1) DE2315801C3 (enExample)
ES (1) ES413188A1 (enExample)
FR (1) FR2182914B1 (enExample)
GB (1) GB1378375A (enExample)
HU (1) HU167305B (enExample)
SE (1) SE402592B (enExample)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5154583A (en) * 1974-11-01 1976-05-13 Kyorin Seiyaku Kk Shinkipirazoro * 1 55a * pirijinjudotaino seizoho
US4097483A (en) * 1974-11-01 1978-06-27 Kyorin Pharmaceutical Co., Ltd. Pyrazolo 1,5-a!pyridines
US4237300A (en) * 1975-12-09 1980-12-02 Merck & Co., Inc. Certain 6-substituted-2-pyridinamines
JPS5968553A (ja) * 1982-10-13 1984-04-18 Automob Antipollut & Saf Res Center 燃料タンク内蔵式燃料ポンプ
JPS6072975U (ja) * 1983-10-26 1985-05-22 ヤンマーディーゼル株式会社 燃料ポンプのエア抜き装置
JPH0621066B2 (ja) * 1984-03-14 1994-03-23 杏林製薬株式会社 ３―イソブチリル―２―イソプロピルピラゾロ〔１，５―ａ〕ピリジンの徐放性医薬品組成物
JPS6263520A (ja) * 1985-09-14 1987-03-20 Kyorin Pharmaceut Co Ltd 抗リウマチ剤
US4925849A (en) * 1987-06-15 1990-05-15 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutically useful pyrazolopyridines
JPH01153633A (ja) * 1987-12-10 1989-06-15 Kyorin Pharmaceut Co Ltd 経皮吸収製剤
EP0355234A1 (en) * 1988-08-25 1990-02-28 Merrell Dow Pharmaceuticals Inc. Pyrazolopyridine derivatives as antiatherosclerotic and antihypercholesterolemic agents
JPH085790B2 (ja) * 1988-11-11 1996-01-24 杏林製薬株式会社 記憶障害改善薬
JPH0256853U (enExample) * 1989-10-04 1990-04-24
JPH06166687A (ja) * 1990-07-18 1994-06-14 Senju Pharmaceut Co Ltd ピラゾロ〔１，５−ａ〕ピリジン化合物、その製造法および用途
PL200923B1 (pl) 1999-08-21 2009-02-27 Nycomed Gmbh Lek zawierający inhibitor PDE w połączeniu z agonistą receptoraß₂ -adrenergicznego oraz zastosowanie połączenia roflumilastu i salmeterolu
EA200500234A1 (ru) 2002-08-19 2005-08-25 Пфайзер Продактс Инк. Комбинированная терапия гиперпролиферативных болезней
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
JP2006522151A (ja) 2003-04-01 2006-09-28 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ 不妊症におけるホスホジエステラーゼ阻害剤
SG141430A1 (en) 2003-05-30 2008-04-28 Ranbaxy Lab Ltd Substituted pyrrole derivatives and their use as hmg-co inhibitors
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
JP2007512337A (ja) 2003-11-21 2007-05-17 コンビナトアールエックス インコーポレーティッド 炎症性障害の治療のための方法および試薬
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
BRPI0618379A2 (pt) 2005-11-08 2011-08-30 Ranbaxy Lab Ltd processo para preparação do hemi-sal de cálcio do ácido (3r,5r) -7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroxime tilfenilamino) carbonil]-pirrol-1-il] -3, 5-diidroxi heptanóico
US8067433B2 (en) 2005-11-09 2011-11-29 Zalicus Inc. Methods, compositions, and kits for the treatment of ophthalmic disorders
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
JP5352452B2 (ja) * 2006-06-06 2013-11-27 メディシノバ， インコーポレイテッド 置換ピラゾロ［１，５−ａ］ピリジン化合物およびその使用方法
ATE547394T1 (de) 2006-12-01 2012-03-15 Bristol Myers Squibb Co N-((3-benzyl)-2,2-(bis-phenyl)-propan-1- aminderivate als cetp-hemmer für die behandlung von atherosklerose und herz-kreislauf- erkrankungen
PL2131841T3 (pl) 2007-01-30 2013-03-29 Avigen Inc Sposoby leczenia bólu ostrego
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US7536799B2 (en) * 2007-06-07 2009-05-26 Keson Industries Chalk line apparatus with strategically located chalk fill opening
US20100226881A1 (en) * 2007-07-11 2010-09-09 Auckland Uniservices Limited PYRAZOLO[1,5-a]PYRIDINES AND THEIR USE IN CANCER THERAPY
CN101842098A (zh) * 2007-08-10 2010-09-22 基因实验室技术有限公司 用于治疗病毒感染的含氮的二环化学实体
JP5263548B2 (ja) * 2007-08-15 2013-08-14 杏林製薬株式会社 イブジラストを有効成分とする脳動脈瘤の予防、形成抑制又は治療剤
ES2627848T3 (es) 2008-06-04 2017-07-31 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
WO2010005520A2 (en) * 2008-06-30 2010-01-14 Concert Pharmaceuticals, Inc. 2-alkyl-3-acylpyrazolo[1,5-a]pyridine derivatives
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
CA2732520A1 (en) * 2008-08-05 2010-02-11 Merck Sharp & Dohme Corp. Therapeutic compounds
US20100092479A1 (en) * 2008-08-18 2010-04-15 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
KR101701943B1 (ko) 2009-11-13 2017-02-02 도레이 카부시키가이샤 당뇨병의 치료 또는 예방약
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
MX357121B (es) 2011-03-01 2018-06-27 Synergy Pharmaceuticals Inc Star Proceso de preparacion de agonistas c de guanilato ciclasa.
ES2395801B1 (es) 2011-06-23 2014-06-06 María Carmen PARDINA PALLEJÀ "pentoxifilina por vía transvaginal para el tratamiento de la infertilidad"
CN102617579A (zh) * 2012-03-28 2012-08-01 黑龙江大学 一种异丁司特的制备方法
EP2958577A2 (en) 2013-02-25 2015-12-30 Synergy Pharmaceuticals Inc. Guanylate cyclase receptor agonists for use in colonic cleansing
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
EP2968439A2 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
CN105143203A (zh) 2013-04-17 2015-12-09 辉瑞大药厂 用于治疗心血管疾病的n-哌啶-3-基苯甲酰胺衍生物
PL3004138T3 (pl) 2013-06-05 2024-07-29 Bausch Health Ireland Limited Ultra-oczyszczeni agoniści peptydowi cyklazy guanylanowej C, sposób ich uzyskiwania i ich zastosowanie
CA2920856C (en) 2013-08-09 2026-03-03 Ardelyx, Inc. Ph modulating compounds for inhibiting gastrointestinal phosphate uptake
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
CN108033959A (zh) * 2018-01-29 2018-05-15 山东省药学科学院 一种异丁司特的化学合成方法
WO2020150473A2 (en) 2019-01-18 2020-07-23 Dogma Therapeutics, Inc. Pcsk9 inhibitors and methods of use thereof
JP2022533251A (ja) 2019-05-21 2022-07-21 アルデリックス， インコーポレイテッド 患者において血清リン酸塩を低下させるための組み合わせ
CN113387947B (zh) * 2021-07-12 2022-07-01 中国科学院成都生物研究所 调节雌激素受体合成活性的吡唑并吡啶衍生物
GB202306663D0 (en) 2023-05-05 2023-06-21 Union Therapeutics As Combination therapy

Also Published As

Publication number Publication date
AR197709A1 (es) 1974-04-30
HU167305B (enExample) 1975-09-27
SE402592B (sv) 1978-07-10
GB1378375A (en) 1974-12-27
CA989843A (en) 1976-05-25
DE2315801A1 (de) 1973-10-11
US3850941A (en) 1974-11-26
DE2315801B2 (de) 1978-06-22
JPS4897898A (enExample) 1973-12-13
ES413188A1 (es) 1976-01-16
AU5376173A (en) 1974-09-26
FR2182914B1 (enExample) 1976-05-14
BE797554A (fr) 1973-07-16
BR7302268D0 (pt) 1974-08-29
FR2182914A1 (enExample) 1973-12-14
JPS5229318B2 (enExample) 1977-08-01

Similar Documents

Publication Publication Date Title
DE2315801B2 (de) 2-Alkyl-3-acyl-pyrazolo [1,5-a] pyridine, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneipräparate
DE2734678C2 (de) Epininester,Verfahren zu ihrer Herstellung und Heilmittel
DE2359536C2 (de) 2,6-Diaminonebularinderivate
EP0049407A1 (de) 6-Hydroxy-2-phenyl-imidazo(4,5-b)pyridine, ihre Herstellung und diese enthaltende Arzneimittel
DE69413398T2 (de) Positiv inotropische und lusitropische pyrrolochinolinonderivate
DE3940021C2 (de) Adenosin-Derivate, deren Herstellung und Verwendung
DE2155578C3 (de) Verfahren zur Herstellung von 8,9-Didehydro- 10-alkoxy-ergolenderivaten
DE3889644T2 (de) Pheophorbidderivate.
EP0184738A2 (de) Neue Imidazoderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE2539867C2 (de) 14,15-Dihydro-3β ,16α -eburnameninderivate
CH649999A5 (de) 10-brom-e-homo-eburnane.
DE2634910C3 (de) Quartare l>Benzylimidazo [1,2-a] pyridiniumsalze und diese enthaltende pharmazeutische Zubereitung
DE2520131C3 (de) 1,1,-Disubstituierte Octahydro-indolo[2,3-a]chinolizine und verfahren zu deren Herstellung
DE2221808C2 (de) Hydrazinopyridazin-Derivate, deren Säureadditionssalze, Verfahren zu deren Herstellung und Heilmittel
DE69221006T2 (de) Mitomycinderivate
DE3876859T2 (de) Cardiotonische tricyclische oxazolone.
DE1242619B (de) Verfahren zur Herstellung von neuen Nikotionsaeureestern
DE2444890A1 (de) Quaternaere 7-substituierte imidazoeckige klammer auf 2,1-b eckige klammer zu -thiazolderivate, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
DE60004054T2 (de) Neue verfahren zur herstellung von 17beta-hydroxy-17alpha-methyl-2-oxa-5alpha-androstane-3-on
DE2328758C2 (de) 4,4-Diphenyl-2-methyl-2-hydroxybutylamine und diese enthaltende therapeutische Zubereitungen
DD236095A5 (de) Verfahren zur herstellung von neuen nitronpovincamsaeure-derivaten
DE2404924A1 (de) Ergolinderivate
DE2732906C2 (de) In 5-Stellung durch einen Aminoalkylrest substituierte Imidazo-isochinolin-dione, Verfahren zu ihrer Herstellung und Arzneimittel
DE2539866C2 (de) 3,4-Dehydro-14,15-dihydro-eburnameninderivate
DE2541485C3 (de) 1-Alkyl-1-(2-cyanäthyl)-1,2,3,4,6,7-hexahydroindolo- [2,3-a] chinolizinderivate

Legal Events

Date Code Title Description
C3 Grant after two publication steps (3rd publication)